Angitia Biopharmaceuticals Guangzhou Limited

This phase 2 trial tests a drug called AGA2115 in 48 Chinese adults and adolescents with osteogenesis imperfecta (types I, III, IV), a condition that makes bones brittle. Participants receive one of three dose schedules by injection under the skin. The study checks for side effec…